Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

External-use pharmaceutical composition formulation with antiphlogistic, swelling-dispersing and analgesic functions, and use

A technology of external drug and composition, applied in the field of external drug composition preparation, which can solve the problems of irritation, anti-inflammation, anti-swelling action time delay, shortening the use time, etc.

Active Publication Date: 2009-05-20
JIANGSU KANION PHARMA CO LTD
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that the onset of aescinate is delayed after administration (it begins to show obvious anti-inflammatory effect after 6 hours), and the appearance of anti-inflammatory and anti-swelling effects has a significant time delay phenomenon, which is beneficial to acute inflammation and edema. Certain adverse effects during treatment
In addition, aescin (or its pharmaceutically acceptable salt) is mostly used for injection clinically. Due to its own nature, it has obvious irritation to blood vessels and causes great pain to patients. Shorten the use time, thus affecting the effect of the treatment
Oral diclofenac has the obvious disadvantages of gastrointestinal irritation, gastrointestinal bleeding and ulcers.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • External-use pharmaceutical composition formulation with antiphlogistic, swelling-dispersing and analgesic functions, and use
  • External-use pharmaceutical composition formulation with antiphlogistic, swelling-dispersing and analgesic functions, and use
  • External-use pharmaceutical composition formulation with antiphlogistic, swelling-dispersing and analgesic functions, and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] Example 1. An external pharmaceutical composition preparation with anti-inflammation, detumescence and analgesic effects, the active ingredient raw materials made into medicine and their weight percentages in the whole preparation are:

[0071] (1) Aescin or its pharmaceutically acceptable salt 0.01%;

[0072] (2) Diclofenac or its pharmaceutically acceptable salt 0.01%;

[0073] The rest are accessories.

Embodiment 2

[0074] Example 2. An external pharmaceutical composition preparation with anti-inflammation, detumescence and analgesic effects, the active ingredient raw materials made into medicine and their weight percentages in the whole preparation are:

[0075] (1) Aescin and its pharmaceutically acceptable salt 20%;

[0076] (2) Diclofenac or its pharmaceutically acceptable salt 10%;

[0077] The rest are accessories.

Embodiment 3

[0078] Example 3. An external pharmaceutical composition preparation with anti-inflammation, detumescence and analgesic effects, the active ingredient raw materials made into medicine and their weight percentages in the whole preparation are:

[0079] (1) Aescin or its pharmaceutically acceptable salt 0.01%;

[0080] (2) Diclofenac or its pharmaceutically acceptable salt 10%;

[0081] The rest are accessories.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an external pharmaceutical composition preparation with functions of resisting inflammation, reducing swelling and relieving pain, which is characterized in that the preparation is prepared by the following effective component raw materials in weight percent of the whole preparation: 0.01 to 20 percent of escin and / or pharmaceutically acceptable salt thereof, 0.01 to 10 percent of diclofenac or pharmaceutically acceptable salt thereof, and the balance being accessories. The external pharmaceutical composition can be made into any pharmaceutically acceptable external dosage form. The preparation can be used for treating symptoms, such as arthralgia, hyperosteogeny, gout, neuropathic pain, injuries from falls, chronic strain diseases and various closed injuries, and the like, and has strong practicability.

Description

technical field [0001] The invention relates to an external pharmaceutical composition preparation with anti-inflammation, detumescence and analgesic effects, which is made of natural medicine and non-steroid analgesic and anti-inflammatory drug; the invention also relates to the use of the preparation. Background technique [0002] Arthralgia, hyperosteogeny, gout, neuropathic pain, bruises and various closed injuries are common and frequently-occurring diseases, which seriously affect people's work, study and daily life. Although there are many Western medicines, most of them have side effects in varying degrees, so sticking and applying externally applied medicines are the easiest and most popular methods for treating the above-mentioned diseases. [0003] At present, there are many kinds of external preparations with anti-inflammatory and analgesic effects. Western medicines are mainly non-steroidal analgesic anti-inflammatory drugs, and most of them use creams, gels and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K31/196A61P19/00
Inventor 丁岗夏月曹亮陆洁
Owner JIANGSU KANION PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com